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The use of abacavir has been linked with increased cardiovascular risk in patients with
human immunodeficiency virus infection; however, the mechanism involved remains un-
clear. We hypothesize that abacavir may impair endothelial function. In addition, based on
the structural similarity between abacavir and adenosine, we propose that abacavir may af-
fect vascular contractility through endogenous adenosine release or adenosine receptors in
blood vessels.
Methods
The relaxation effect of abacavir on rat basilar arteries was studied using the myograph
technique. Cyclic GMP and AMP levels were measured by immunoassay. The effects of
abacavir on nucleoside transporters were studied using radiolabeled nucleoside uptake ex-
periments. Ecto-50 nucleotidase activity was determined by measuring the generation of in-
organic phosphate using adenosine monophosphate as the substrate.
Results
Abacavir induced the relaxation of rat basilar arteries in a concentration-dependent manner.
This relaxation was abolished when endothelium was removed. In addition, the relaxation
was diminished by the nitric oxide synthase inhibitor, L-NAME, the guanylyl cyclase inhibi-
tor, ODQ, and the protein kinase G inhibitor, KT5820. Abacavir also increased the cGMP
level in rat basilar arteries. Abacavir-induced relaxation was also abolished by adenosine
A2 receptor blockers. However, abacavir had no effect on ecto-5’ nucleotidase and nucleo-
side transporters. Short-term and long-term treatment of abacavir did not affect acetylcho-
line-induced relaxation in rat basilar arteries.
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Conclusion
Abacavir induces acute endothelium-dependent relaxation of rat basilar arteries, probably
through the activation of adenosine A2 receptors in endothelial cells, which subsequently
leads to the release of nitric oxide, resulting in activation of the cyclic guanosine monophos-
phate/protein kinase G-dependent pathway in vascular smooth muscle cells. It is speculat-
ed that abacavir-induced cardiovascular risk may not be related to endothelial dysfunction
as abacavir does not impair relaxation of blood vessels. The most likely explanation of in-
creased cardiovascular risk may be increased platelet aggregation as suggested by
other studies.
Introduction
Use of the nucleoside reverse transcriptase inhibitor (NRTI), abacavir, in the treatment of pa-
tients infected with the human immunodeficiency virus (HIV) may be associated with in-
creased cardiovascular risk [1]. An observational study conducted by the Data Collection on
Adverse events of Anti-HIV Drugs (D:A:D) study group reported that patients exposed to aba-
cavir had a higher risk of myocardial infarction and stroke even after adjustment for conven-
tional cardiovascular risk factors [2]. A strong correlation between abacavir and increased risk
of myocardial infarction has also been reported in other cohort studies [3–5]. However, clinical
trials sponsored by the manufacturer of abacavir (GlaxoSmithKline) and other studies claim
that abacavir therapy does not increase the risk of myocardial ischemic events [6–8].
The mechanism of abacavir-induced increased cardiovascular risk is unknown. Theoretical-
ly, the association between abacavir and increased cardiovascular risk may be related to endo-
thelial dysfunction. An in vitro experiment demonstrated that abacavir decreases the
expression of endothelial nitric oxide synthase (eNOS) and increases oxidative stress in porcine
and human pulmonary arterial endothelial cells [9]. In addition, abacavir may interfere with
purine signaling pathways and may lead to activation of T lymphocytes, which causes vascular
damage [10]. It has been postulated that abacavir may inhibit the activity of ecto-5 nucleotid-
ase, resulting in decreased release of the anti-inflammatory nucleoside, adenosine, and in-
creased release of the pro-inflammatory agents, adenosine triphosphate and adenosine
diphosphate [11]. Levels of inflammatory markers such as C-reactive protein,metalloprotei-
nase-9 and myeloperoxidase were also found to be elevated after switching antiretroviral thera-
py to abacavir [12]. However, several studies have reported that levels of inflammatory or
coagulopathic biomarkers are not significantly increased in patients on abacavir therapy [13–
16]. Abacavir, didanosine and tenofovir have no effect on coronary endothelial cell gene tran-
scription and protein expression of proinflammatory molecules such as vascular cell adhesion
molecule-1, intracellular adhesion molecule-1, monocyte chemotactic protein-1 and interleu-
kin-6. In addition, these agents do not affect gene expression of the intracellular reactive oxy-
gen species producing enzyme, NADPH oxidase, and the apoptosis regulating molecules [17].
Similar conflicting results were also observed in a single study in which the levels of vascular
cell adhesion molecule-1 were decreased, while those of interleukin-6 were elevated during aba-
cavir treatment [18]. Therefore, the effect of abacavir on endothelial function remains obscure.
We hypothesize that abacavir may impair endothelial function. In addition, abacavir is a gua-
nosine analog with a chemical structure similar to the physiological vasodilator adenosine.
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Therefore, we postulate that abacavir may affect vascular contractility by altering endogenous
adenosine release or adenosine receptors in blood vessels.
Materials and Methods
Ethical approval of the study protocol
All experiments performed in this study were approved by the Committee on the Use of Live
Animals in Teaching and Research of the University of Hong Kong.
Animal studies
Abacavir can penetrate deep into the central nervous system [19,20] and remains at a detect-
able concentration in the brain for a considerable time [20,21]. One cohort study showed that
abacavir was associated with an increased risk of cerebrovascular events [22]. Therefore, rat
basilar arteries were used as the primary model of blood vessels in the present study. Male
Sprague–Dawley rats (8–10 weeks; 300–350 g) were used. The rats were kept in a temperature
and humidity controlled room, with free access to food and water, and maintained under a
12:12 h light-dark cycle. The rats were anesthetized by intraperitoneal injection of sodium pen-
tobarbitone (70 mg/kg) with heparin (0.5 U/kg) to avoid the formation of blood clots. The
brains were quickly dissected and transferred to ice-cold Krebs–Henseleit solution (KHS; com-
position in mM: NaCl 120, KCl 4.76, NaHCO3 25, NaH2PO4 1.18, CaCl2 1.25, MgSO4 1.18,
glucose 5.5, at pH 7.4). Basilar arteries were isolated under a dissecting microscope. To study
the short-term effect of abacavir, the isolated rat basilar arteries were incubated in culture me-
dium containing abacavir (10 μM) at 37°C in 5% CO2 / 95% air for 24 h. The arteries were
washed before mounting in the myograph system. To study the long-term effect of abacavir,
rats were fed abacavir (16 mg/kg/day or 160 mg/kg/day, intragastrically) by gavage for 4 weeks.
The 4- week period was chosen based on a previous study which showed that antiretroviral
agents such as azidothymidine could induce endothelial dysfunction in rats after treatment for
30 days [23]. Abacavir was dissolved in 5% methylcellulose. Rats fed with the same volume of
5% methylcellulose served as the control group. Each group contained eight rats.
Measurement of vascular contractility
Rings of basilar arteries were held between two 40-μm tungsten wires mounted on the jaw of a
Mulvany–Halpern myograph filled with 8 mL KHS to record isometric tension. The bath solu-
tion was continuously gassed with 95% O2/5% CO2 and maintained at 37°C. Basilar artery
rings were equilibrated for 1 h under 0.5 g before experimentation. The bath solution was
changed every 15 min. Basal tension was readjusted if necessary.
After equilibration, the arterial rings were stimulated twice with 60 mM KCl to obtain maxi-
mal contraction. The rings were contracted using endothelin-1 (1–10 nM) to obtain maximal
contraction and then relaxed with acetylcholine (10 μM). Arteries which were relaxed by more
than 80% reflected the presence of endothelium. When necessary, endothelium-denuded ves-
sels were prepared by gently rubbing the intimal surface of the rings with hair. Loss of the re-
laxation response to acetylcholine indicated the absence of endothelia. Drugs were removed by
repeatedly changing the bath solution. After the re-establishment of baseline tension, rings
were again contracted using endothelin-1 (1–10 nM), which was approximately 90% of the
maximal contraction induced by 60 mM KCl. To study the mechanism of action, arterial rings
were incubated with different pharmacological inhibitors for 30 min before contraction with
endothelin-1. The level of contraction induced by endothelin-1 in rat basilar arteries was not
significantly altered by the pharmacological agents used in the present study. Cumulative
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relaxation–response curves were constructed by stepwise addition of different relaxation agents
at half-log basis. After the experiments, the arteries were sectioned and stained using hematox-
ylin and eosin to ensure that the arteries were grossly normal after the drug treatments.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were purchased from the American Type
Culture Collection (Manassas, VA, USA). They were cultured in Ham's Kaighn's Modification
F12K medium supplemented with 10% (v/v) fetal bovine serum (FBS), 10,000 units/mL peni-
cillin, 10,000 μg/mL streptomycin, 25 μg/mL amphotericin, 0.1 mg/mL heparin and 0.05 mg/mL
endothelial cell growth supplement.
PK15NTD/ENT1 and PK15NTD/ENT2 cells were used to study the effects of abacavir on
nucleoside transporters. These cells are derived from the nucleoside transporter-deficient cell
line PK15NTD and stably transfected with clone human ENT1 and ENT2 [24]. Cells were cul-
tured in Eagle’s minimal essential medium/Earle’s balanced salt solution (1:1) with 0.1 mM
non-essential amino acids, 1 mM pyruvate, 10% (v/v) FBS, 100 units/mL penicillin, 100 μg/mL
streptomycin and 0.25 μg/mL amphotericin. Cells were incubated in 75 cm2 culture flasks at
37°C with 5% CO2/95% air. The medium was changed every 3–4 days. Confluent cells were
used for further experiments.
Uptake assay
The uptake assay was carried out as previously described [25]. Cells were washed twice with
HEPES-buffered Ringer’s solution (135 mMNaCl, 5 mM KCl, 3.33 mMNaH2PO4, 0.83 mM
Na2HPO4, 1.0 mM CaCl2, 1.0 mMMgCl2, 10 mM glucose, and 5 mMHEPES at pH 7.4). To
study abacavir uptake in HUVECs, 300 μL of [3H]abacavir (10 μM, 2 μCi/mL) in HEPES-buff-
ered solution was added to the cells at different time points at room temperature to allow [3H]
abacavir uptake. To study the effects of abacavir on nucleoside transporters in HUVECs,
ENT1/PK15NTD cells and ENT2/PK15NTD cells, [3H]adenosine (10 μM, 2 μCi/mL) was
added to the cells for 4 min at room temperature. Different concentrations of abacavir were
added simultaneously with [3H]adenosine. To determine the passive uptake of adenosine,
monolayers of cells were incubated in buffer containing [3H]adenosine in the presence of
0.5 mM NBMPR (which blocks all adenosine uptake by ENT1 and ENT2). The uptake process
was terminated by washing the plates rapidly with ice-cold phosphate-buffered saline (PBS)
buffer. The plates were air-dried and 500 μL of 5% Triton-X was added to lyse cells overnight.
Cell lysates were mixed with 2 mL of scintillation liquid. Radioactivity was measured using a β-
scintillation counter.
Determination of levels of cyclic GMP and AMP
Rat basilar arteries were incubated in oxygenated KHS at 37°C in the absence or presence of
abacavir (30 μM) or ODQ (10 μM; a guanylyl cyclase inhibitor) for 20 min. cGMP and cAMP
from arteries were extracted and their concentrations were determined using commercially
available kits (Cyclic GMP/AMP EIA kit; Cayman Chemical, Ann Arbor, MI, USA).
Determination of ecto-50 nucleotidase activity
Ecto-50 nucleotidase catalyzes the metabolism of adenosine monophosphate to adenosine to
form inorganic phosphate. Therefore, the amount of inorganic phosphate formed can reflect
the activity of ecto-50 nucleotidase. The principle of this assay is based upon the measurement
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of inorganic phosphate, which reacts with ammonium molybdate to form a colored product at
an absorbance of 750 nm. The assay procedure has been previously described [26].
Materials
Ham's Kaighn's Modification F12K medium and Eagle’s minimal essential medium/Earle’s bal-
anced salt were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). KT 5720
and KT 5823 were purchased from Calbiochem EMD Chemical Group (Gibbstown, NJ, USA).
Abacavir and [3H]abacavir were purchased fromMoravek Biochemicals and Radiochemicals
(Brea, CA, USA). cGMP and cAMP EIA Kits were purchased from Cayman Chemical. AMP,
indomethacin (INDO), L-NAME, ODQ, SQ 22536, TRAM-34 and UCL 1684 were purchased
from Sigma–Aldrich (St. Louis, MO, USA).
Statistics
The Kolmogorov-Smirnov test was used to examine the normal distribution of the data. Data
are mean ± standard error mean (S.E.M.). The Student’s t-test and analysis of variance (one-
way ANOVA) were used for paired and multiple variants, respectively. Concentration–re-
sponse curves were fitted by a four-parameter logistic function curve, and half-maximal inhibi-
tory concentration (IC50) values were determined. P<0.05 was considered significant. All
statistical tests were undertaken using GraphPad Prism version 5.01 (GraphPad, San Diego,
CA, USA).
Results
Endothelium-dependent relaxation induced by abacavir
Abacavir had no contractile effect on rat basilar arteries with basal tone (data not shown).
However, abacavir induced the relaxation of rat basilar arteries in a concentration-dependent
manner with an IC50 value of 5.46 μM (Fig 1). This abacavir-induced relaxation was greatly di-
minished when the endothelium was removed from rat basilar arteries. It is well known that
the major relaxing factors released from endothelial cells are nitric oxide (NO), prostacyclin
(PGI2) and endothelium-derived hyperpolarizing factor (EDHF). To study which factors were
responsible for the abacavir-induced relaxation response, the effects of L-NAME (100 μM; an
endothelial NO synthase inhibitor), indomethacin (10 μM; a cyclooxygenase inhibitor) and
Fig 1. Effect of abacavir on the relaxation of rat basilar arteries. Abacavir-induced relaxation of rat
basilar arteries was measured in the presence (+EC) or absence (–EC) of endothelial cells. (A) Changes in
tension were expressed as the percentage decrease in response to contraction caused by endothelin-1 (ET-
1; 1–10 nM). (B) Sample trace showing the effect of endothelium removal on abacavir-induced relaxation.
Values are means ± S.E.M of six to eight sets of experiments and statistical comparisons were made using
ANOVA. ** P<0.01 compared with control.
doi:10.1371/journal.pone.0123043.g001
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TRAM-34 plus UCL 1684 (both at 1 μM; inhibitors of EDHF-mediated responses) were stud-
ied. Abacavir-induced relaxation of rat basilar arteries was not affected when arteries were pre-
treated with indomethacin or TRAM-34 plus UCL 1684 (Fig 2). In contrast, abacavir-induced
relaxation was abolished by L-NAME.
Involvement of the cGMP/PKG pathway in abacavir-induced relaxation. Abacavir-in-
duced relaxation was examined in the presence of ODQ (10 μM; a guanylyl cyclase inhibitor)
Fig 2. Involvement of NO, prostacyclin and EDHFs on abacavir-induced relaxation of rat basilar
arteries. Rings of rat basilar arteries were treated with L-NAME (100 μM), indomethacin (INDO; 10 μM), or
TRAM-34 (1 μM) plus UCL 1648 (1 μM) for 30 min. Rings without inhibitor treatment served as controls.
Abacavir-induced relaxation of basilar arteries was then measured. (A) Changes in tension were expressed
as the percentage decrease in response to contraction caused by endothelin-1 (ET-1; 1–10 nM). (B) Sample
trace showing the effect of L-NAME on abacavir-induced relaxation. Values are means ± S.E.M of five sets of
experiments and statistical comparisons were made using ANOVA. *** P<0.005 compared with control.
doi:10.1371/journal.pone.0123043.g002
Fig 3. Role of the cGMP signaling pathway in abacavir-induced relaxation of rat basilar arteries.Rings
of rat basilar arteries were treated with ODQ (10 μM) or KT 5823 (1 μM) for 30 min. Rings without inhibitor
treatment served as controls. Abacavir-induced relaxation of basilar arteries was then measured. Changes in
tension were expressed as the percentage decrease in response to contraction caused by endothelin-1 (ET-
1; 1–10 nM). Values are means ± S.E.M of five sets of experiments and statistical comparisons were made
using ANOVA. *** P<0.005 compared with control.
doi:10.1371/journal.pone.0123043.g003
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and KT 5823 (1 μM; a protein kinase G inhibitor) to study the contribution of the cGMP/PKG-
dependent pathway in this process. ODQ and KT 5823 greatly reduced abacavir-induced relax-
ation of basilar arteries (Fig 3). In contrast, SQ 22536 (10 μM; an adenylyl cyclase inhibitor)
and KT 5720 (1 μM; a protein kinase A inhibitor) had no effect on abacavir-induced relaxation
of basilar arteries (Fig 4).
To further confirm that abacavir-induced relaxation was mediated by the cGMP signaling
pathway, but not by the cAMP signaling pathway, the effects of abacavir on the levels of cGMP
and cAMP in rat basilar arteries were investigated. The intracellular concentration of cGMP in
rat basilar arteries was increased by abacavir (30 μM) (Fig 5). The increased level of cGMP by
abacavir was diminished by ODQ (10 μM). In contrast, abacavir had no effect on cAMP level
in rat basilar arteries (Fig 6).
Role of adenosine receptors in abacavir-induced relaxation. It is hypothesized that aba-
cavir may be transported into endothelial cells, thereby stimulating the synthesis of NO in the
latter, which induces relaxation of vascular smooth muscle cells. Abacavir uptake by HUVECs
increased with time (Fig 7). However, [3H]abacavir uptake by HUVECs was negligible in the
first 5 min. This abacavir uptake was not inhibited by an excess of non-radioactive abacavir, in-
dicating that abacavir uptake in HUVECs was primarily mediated by passive diffusion.
Another hypothesis is that abacavir may act on adenosine receptors to induce relaxation as
abacavir is a nucleoside analog and its chemical structure is similar to that of the physiological
vasodilator, adenosine [27,28]. To determine whether abacavir-induced relaxation of basilar
arteries was adenosine receptor-mediated, the effects of CGS-15943 (1 μM; a non-selective
adenosine receptor antagonist) and ZM-241385 (1 μM; a selective A2 receptor antagonist) were
examined. CGS-15943 and ZM-241385 abolished the relaxation effect of abacavir (Fig 8).
Fig 4. Role of the cAMP signaling pathway in abacavir-induced relaxation of rat basilar arteries.Rings
of rat basilar arteries were treated with SQ 22536 (10 μM) or KT 5720 (1 μM) for 30 min. Rings without
inhibitor treatment served as controls. Abacavir-induced relaxation of basilar arteries was then measured.
Changes in tension were expressed as the percentage decrease in response to contraction caused by
endothelin-1 (ET-1; 1–10 nM). Values are means ± S.E.M of five sets of experiments and statistical
comparisons were made using ANOVA.
doi:10.1371/journal.pone.0123043.g004
Abacavir Relaxes Basilar Arteries
PLOS ONE | DOI:10.1371/journal.pone.0123043 April 8, 2015 7 / 18
Further experiments were carried out to ascertain if abacavir could act on adenosine recep-
tors indirectly through the simulation of ecto-50 nucleotidase, which increased the generation
of endogenous adenosine. Our results showed that the activity of ecto-50 nucleotidase was un-
changed after HUVECs were incubated with abacavir for 24 h (Fig 9). Another experiment was
undertaken to determine if abacavir could inhibit nucleoside transporters, thereby reducing the
disappearance of extracellular adenosine. Although adenosine uptake by HUVECs, ENT1/
PK15NTD cells and ENT2/PK15NTD cells was inhibited by 100 μM abacavir by approximately
Fig 5. Effect of abacavir on the concentration of cGMP in rat basilar arteries.Rat basilar arteries were
pretreated with or without ODQ (10 μM) for 30 min and then stimulated with or without abacavir (30 μM) for
20 min. Arteries not treated with ODQ and abacavir served as controls. cGMP content in the arteries was
determined using an ELISA kit. Values are means ± S.E.M. of three sets of experiments and statistical
comparisons were made using ANOVA. ** P<0.01 and *** P<0.005 compared with control.
doi:10.1371/journal.pone.0123043.g005
Fig 6. Effect of abacavir on the concentration of cAMP in rat basilar arteries. Rat basilar arteries were
incubated without (control) or with 30 μM abacavir for 20 min. cAMP content in arteries was determined using
an ELISA kit. Values are means ± S.E.M. of three sets of experiments and statistical comparisons were made
using student’s t-test.
doi:10.1371/journal.pone.0123043.g006
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40%, abacavir had no effect on adenosine uptake when the concentration was less than 10 μM
(Fig 10).
Effect of short-term and long-term treatment with abacavir on relaxation
Acetylcholine-induced endothelium-dependent relaxation was not altered when basilar arteries
were pre-incubated with abacavir for 24 h (10 μM) (Fig 11). For long-term treatment, rats were
Fig 7. Uptake of [3H]abacavir by HUVECs.Uptake of [3H]abacavir (2 μCi/mL, 1 nM) by HUVECs was
measured after incubation with [3H]abacavir with or without unlabeled abacavir (20 μM) for 1, 6, 12, and
20 min at room temperature. Values are means ± S.E.M. of three sets of experiments carried out in triplicate
and statistical comparisons were made using ANOVA.
doi:10.1371/journal.pone.0123043.g007
Fig 8. Effects of adenosine receptor antagonists on abacavir-induced relaxation of rat basilar
arteries. Rings of rat basilar arteries were treated with CGS-15943 (1 μM) or ZM-241385 (1 μM) for 30 min.
Rings without antagonist treatment served as controls. Abacavir-induced relaxation of rat basilar arteries was
then measured. (A) Changes in tension were expressed as a percentage decrease in response to contraction
caused by endothelin-1 (ET-1; 1–10 nM). (B) Sample trace showing the effects of CGS-15943 and ZM-
241385 on abacavir-induced relaxation. Values are means ± S.E.M of four to five sets of experiments and
statistical comparisons were made using ANOVA. ***P<0.005 versus control.
doi:10.1371/journal.pone.0123043.g008
Abacavir Relaxes Basilar Arteries
PLOS ONE | DOI:10.1371/journal.pone.0123043 April 8, 2015 9 / 18
fed abacavir (16 mg/kg/day or 160 mg/kg/day) for 4 weeks. The weight of the rats was
537.4 ± 12.5 g (control) vs 488.6 ± 5.9 g (treated with abacavir 16 mg/kg); and 484.3 ± 5.064 g
(control) vs 479.5 ± 15.02 g (treated with abacavir 160 mg/kg). There was no significant
Fig 9. Ecto-50-nucleotidase activity in HUVECs.HUVECs were treated without (control) or with abacavir
(10 μM) for 24 h and the activity of ecto-5’ nucleotidase measured. Values are means ± S.E.M. of three sets of
experiments carried out in triplicate and statistical comparisons were made using Student’s t-test.
doi:10.1371/journal.pone.0123043.g009
Fig 10. Effects of abacavir on adenosine uptake in HUVECs, PK15NTD/ENT1 cells and PK15NTD/
ENT2 cells. [3H]adenosine uptake (10 μM, 2 μCi/mL) by HUVECs (□), PK15NTD/ENT1 cells (■) and
PK15NTD/ENT2 cells (▲) was measured at room temperature for 4 min in the presence of abacavir (1 nM to
100 μM). Values are means ± S.E.M. of three experiments carried out in triplicate and statistical comparisons
were made using ANOVA.
doi:10.1371/journal.pone.0123043.g010
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difference between the controls and abacavir treatment groups. Acetylcholine-induced endo-
thelium-dependent relaxation in rat basilar arteries was unaffected when rats were treated with
both dosages of abacavir (Fig 12A and 12B). Endothelium-independent relaxation was also
studied using sodium nitroprusside. 10 nM of sodium nitroprusside induced a relaxation re-
sponse of 64.4 ± 6.3% and 66.8 ± 8.5% in control arteries and arteries incubated with abacavir
Fig 11. Effects of short-term treatment with abacavir on acetylcholine-induced relaxation of rat
basilar arteries. Basilar arterial rings were treated with abacavir (10 μM) for 24 h. Rings not treated with
abacavir served as controls. Acetylcholine (Ach)-induced relaxation of basilar arteries was then measured.
Changes in tension were expressed as a percentage decrease in response to contraction caused by
endothelin-1 (ET-1 1–10 nM). Values are means ± S.E.M. of five to eight sets of experiments and statistical
comparisons were made using ANOVA.
doi:10.1371/journal.pone.0123043.g011
Fig 12. Effect of long-term treatment of abacavir on acetylcholine-induced relaxation of rat basilar
arteries. Rats were treated with (A) 16 mg/kg/day of abacavir and (B) 160 mg/kg/day of abacavir for 4 weeks.
Rats not treated with abacavir served as controls. Acetylcholine (Ach)-induced relaxation of basilar arteries
was then measured. Changes in tension were expressed as a percentage decrease in response to
contraction caused by endothelin-1 (ET-1; 1–10 nM). Values are means ± S.E.M. of eight sets of experiments
and statistical comparisons were made using ANOVA.
doi:10.1371/journal.pone.0123043.g012
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for 24 h, respectively. Sodium nitroprusside-induced relaxation was 48.9 ± 7.4% and
52.3 ± 8.2% in control rats and rats treated with 160 mg/kg of abacavir, respectively.
Discussion
Unexpectedly and opposite to our hypothesis that abacavir may impair endothelial function,
our results showed that abacavir induced endothelium-dependent relaxation of rat basilar ar-
teries. These findings are novel, thus further experiments were carried out to investigate the
mechanism of abacavir-induced relaxation. It is well established that the endothelium releases
endothelium-dependent relaxing factors such as NO, PGI2 and EDHFs upon stimulation
[29,30]. In the present study, different pharmacological agents were used to determine which
factors were responsible for the effect of abacavir. Studies have demonstrated that NO is the
major factor responsible for the basal tone of rat basilar arteries [31–33]. The present study
consistently showed that the relaxation induced by abacavir could be attenuated only by the
NO synthase inhibitor, L-NAME. This finding indicated that abacavir-induced relaxation was
solely NO-mediated. PGI2 and EDHF were probably not involved in abacavir-induced relaxa-
tion as the presence of indomethacin and TRAM-34 and UCL 1684 did not reverse the relaxa-
tion response. These findings are unsurprising as basilar arteries are considered to be large
cerebral arteries, and it has been demonstrated that the EDHF response is more prominent in
smaller arterioles [32,34].
It is well known that NO released from endothelial cells can activate soluble guanylyl cyclase
in vascular smooth muscle cells, which catalyzes the formation of cGMP. The increase in intra-
cellular cGMP level in turn activates protein kinase G leading to the stimulation of a cascade of
phosphophorylation/dephosphorylation of proteins which relaxes vascular smooth muscle
cells [35–38]. Consistent with this phenomenon, our results showed that abacavir-induced re-
laxation was inhibited by the guanylyl cyclase inhibitor, ODQ, and the protein kinase G inhibi-
tor, KT 5823. Soluble guanylyl cyclase is highly expressed in the cerebral vasculature [32,39–
41]. In our experiments, an enzyme-linked immunosorbent assay was used to measure the ef-
fect of abacavir on intracellular levels of cGMP. Arteries were incubated with abacavir for 20
min as the arteries were fully relaxed by abacavir at around 20 min. We postulated that cGMP
should reach a maximum level within 20 min. Our data showed that abacavir treatment in-
creased the intracellular level of cGMP in basilar arteries, and that the increased level of cGMP
was abolished by ODQ. Taken together, we are convinced that activation of the NO/soluble
guanylyl cyclase/cGMP/protein kinase G signaling pathway is the major mechanism by which
abacavir induces relaxation.
The cAMP signaling pathway is another common mechanism involved in the vasodilatory
response. An increase in intracellular cAMP level can activate protein kinase A, which induces
the relaxation of vascular smooth muscle cells. Interestingly, the cAMP signaling pathway may
‘crosstalk’ with the cGMP signaling pathway. This crosstalk mechanism is present in the regu-
lation of cerebral vasodilatation [41]. Therefore, it is not impossible that cAMP may play a part
in abacavir-induced relaxation. However, our results showed that the adenylyl cyclase inhibi-
tor, SQ 22583, and the PKA inhibitor, KT 5720, did not alter abacavir-induced relaxation. In
good agreement with these results, the results of immunoassay showed that abacavir did not in-
crease the intracellular concentration of cAMP in rat basilar arteries. These data suggest that
the cAMP/PKA signaling pathway does not contribute significantly to abacavir-induced
relaxation.
The relaxation effect of abacavir occurred in<1 min. However, abacavir uptake by endothe-
lial cells was very slow, and the amount of abacavir which accumulated within endothelial cells
in 1 min was negligible. This finding indicated that the vasorelaxing effect of abacavir was
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probably mediated through membrane receptors rather than intracellular mechanisms. Abaca-
vir is a purine nucleoside analog. Adenosine, an endogenous purine nucleoside, can dilate dif-
ferent vascular beds through stimulation of adenosine receptors [42,43]. It was suspected that
abacavir may induce relaxation through stimulation of adenosine receptors. Interestingly, aba-
cavir-induced relaxation was attenuated by CGS-15943 (a non-selective adenosine receptor an-
tagonist) and ZM-241385 (a selective adenosine A2 receptor antagonist). This finding
indicated that the abacavir effect was mediated by adenosine A2 receptors. Several studies have
demonstrated that adenosine induces vasodilatation through a direct action on vascular
smooth muscle cells. However, adenosine receptors are also found in endothelial cells, and
adenosine can dilate blood vessels partly through endothelium-dependent mechanisms [44].
By acting on different A2 receptors on endothelial cells and vascular smooth muscle cells in
coronary arteries, adenosine can induce endothelium-dependent NO-mediated relaxation and
endothelium-independent ATP-sensitive potassium channel-mediated relaxation, respectively
[45]. We demonstrated that abacavir-induced relaxation was endothelium-dependent, thus we
can assume that abacavir stimulated A2 receptors on endothelial cells, which subsequently re-
leased NO causing relaxation of vascular smooth muscle. However, the adenosine receptors
(A2A or A2B) involved in the abacavir-induced response could not be confirmed. A2A and A2B
receptors are predominantly expressed on endothelial cells, and A2B receptors have been re-
ported to mediate the adenosine-induced dilatation of cerebral arterioles [45–47]. Although
ZM-241385 shows a higher affinity to A2A receptors compared with A1 and A3 receptors, it is
suspected that ZM-241385 can also bind to A2B receptors [48,49]. In addition, it is accepted
that activation of A2 receptors leads to an increase in intracellular cAMP [50,51]. However, the
present study showed that abacavir increased the level of cGMP (but not cAMP) in basilar ar-
teries. The reason for this discrepancy is not known, but may be due to differences in vascular
beds. In accordance with the results in the present study, it has been reported that adenosine
relaxes intracerebral arterioles through cGMP-dependent mechanisms rather than cAMP-de-
pendent mechanisms [43].
It is not known if abacavir acts upon adenosine receptors directly or indirectly through the
increased extracellular concentration of endogenous adenosine. The extracellular adenosine
concentration is controlled by (i) ecto-50 nucleotidase, which produces adenosine through con-
version from adenosine monophosphate and (ii) an adenosine transport system which removes
extracellular adenosine by taking it up into cells. The present study showed that abacavir had
no effect on ecto-50 nucleotidase. The major adenosine transport systems in endothelial cells
are ENT1 and ENT2. The former can transport NRTIs such as didanosine and zalcitabine,
whereas ENT2 can transport azidothymidine at low affinity [52,53]. The present study showed
that abacavir (>100 μM) inhibited adenosine uptake by ENT1 and ENT2. Theoretically, the
blockade of ENT1 and ENT2 should increase the local concentrations of adenosine in the vi-
cinity of adenosine receptors. However, this proposed mechanism does not account for the re-
laxation effect of abacavir as 10 μM abacavir relaxed basilar arteries by>50%, however, this
concentration of abacavir was not high enough to inhibit ENT1 and ENT2. Therefore, we pos-
tulate that abacavir may stimulate adenosine A2 receptors directly as they have a similar chem-
ical structure to purine nucleosides.
Studies have shown that short-term (24 h) treatment of porcine arteries with antiviral drugs
causes impairment of relaxation [9,54]. Therefore, the effect of short-term abacavir treatment
on vascular contractility was investigated. An abacavir concentration of 10 μMwas used in the
present study as this is the plasma concentration of abacavir [9]. Short-term treatment of aba-
cavir did not affect acetylcholine-mediated and sodium-nitroprusside-mediated relaxation of
basilar arteries. Our results did not agree with those from a recent study which reported that
endothelium-dependent vasorelaxation in porcine pulmonary arteries and human pulmonary
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arterial endothelial cells was impaired when the arteries were incubated with abacavir for 24 h
[9]. Indeed, several clinical studies have demonstrated that antiviral therapy is linked to a
higher incidence of pulmonary hypertension [55,56]. This discrepancy may be due to the use
of different experimental models. We also suspect that abacavir-induced endothelial dysfunc-
tion may be specific in certain vascular beds (e.g., pulmonary arteries but not basilar arteries).
HIV-infected patients receive life-long antiviral therapy. Therefore, the long-term impact
of abacavir on vascular health was also studied. Two dosages of abacavir, 16 mg/kg/day and
160 mg/kg/day, were used; 16 mg/kg is the daily dosage used clinically [57]. The dosage for hu-
mans and rats may not be identical due to differences in absorption, metabolism or excretion.
However, pharmacokinetic data on abacavir in rats are not available, thus a higher dosage (ten-
fold higher than the dosage for humans) was also used. Although abacavir therapy increases
the risk of cardiovascular events such as myocardial infarction and stroke, the present study
showed that the treatment of rats with abacavir (16 mg/kg/day and 160 mg/kg/day) for 28 days
had no effect on the endothelium-dependent and endothelium-independent relaxation of basi-
lar arteries. Indeed, our experimental results were consistent with a cohort study which showed
that abacavir did not significantly increase the prevalence of cerebrovascular accidents [8].
The major objective of the present study was to determine the impact of abacavir on vascu-
lar contractility. We showed that short-term and long-term treatment of abacavir did not in-
hibit endothelium-dependent and endothelium-independent relaxation. Interestingly, we
found that abacavir may interact with adenosine A2 receptors on the endothelium, thereby in-
ducing NO release which causes relaxation of blood vessels. Nitric oxide level was not mea-
sured in our study due to technical difficulties in isolating enough endothelial cells from rat
basilar arteries for biochemical assay. HUVECs may be used instead of rat basilar endothelial
cells, however, it is generally agreed that the capacity of HUVECs to produce NO is relatively
low and a detectable amount of NO can only be measured after several hours of drug incuba-
tion. In theory, abacavir-induced NO release should potentiate the acetylcholine-mediated re-
laxation of blood vessels, however, this phenomenon was not observed in our study when the
arteries were incubated with abacavir for 24 h or when the rats were treated with abacavir for 4
weeks. This may be due to two reasons. First, the adenosine receptors may be downregulated
or desensitized after treatment with abacavir. Further study is required to prove this hypothe-
sis. The second explanation is that abacavir was washed away before the isometric tension of
arteries was measured in the myograph system (as mentioned in the methodology). The
threshold concentration of abacavir which induced a direct vasorelaxing effect was ~10 μM,
which is comparable to the plasma concentration in patients who receive the clinical dosage of
abacavir [9]. The implications of this direct vasorelaxing effect of abacavir is not known, how-
ever, at the very least, the increase in cardiovascular risk caused by abacavir is unlikely to be
due to endothelial dysfunction.
It has been reported that NRTIs cause endothelial dysfunction in rats and mice by increas-
ing the concentration of the superoxide anion [58,59]. However, abacavir is a novel NRTI
which does not inhibit polymerase γ in mitochondria. Theoretically, it is unlikely that abacavir
causes mitochondrial toxicity, thus the production of reactive oxygen species is reduced
[29,60–62]. This probably explains why endothelial dysfunction in the presence of abacavir
was not observed.
An authoritative review has strongly recommended the inclusion of abacavir in the initial
treatment regimen for HIV-infected patients [63]. In fact, the US Food and Drug Administra-
tion (FDA) is currently re-evaluating the overall risks and benefits of abacavir. This evaluation
may result in the need to revise product labeling. As a precaution, the underlying risk of coro-
nary heart disease or stroke should be considered when prescribing antiretroviral therapies (in-
cluding abacavir), and action should be taken to minimize all modifiable risk factors (e.g.,
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hypertension, hyperlipidemia, diabetes mellitus, smoking). Prevention of the adverse cardio-
vascular effects of abacavir is a long-term goal. The present study showed that abacavir relaxes,
but does not constrict blood vessels, indicating that the cardiovascular risk caused by abacavir
may not be related to its effect on vascular tone. Instead, increased platelet activity by abacavir
may be one of the major mechanisms leading to higher cardiovascular events [64,65]. Theoreti-
cally, abacavir may stimulate endothelial cells to release NO, which should prevent platelet ag-
gregation. However, the uptake of abacavir into platelets is high. Unlike that in vascular cells
where the cellular uptake of abacavir is negligible, abacavir can be converted into the active me-
tabolite carbovir triphosphate inside the cytoplasm of platelets. Carbovir triphosphate is able to
blunt the increase in intraplatelet cGMP through the inhibition of guanylyl cyclase and thus
acutely enhances platelet aggregation [65]. Nevertheless, the vasorelaxing effects of abacavir
may still be a concern. The incidence of abacavir hypersensitivity is 4.3%, of which 7% of
hypersensitivity cases demonstrate symptoms of hypotension [66]. It is not known whether the
relaxation effect of abacavir may potentiate the severity of hypotension. In addition, there is ev-
idence of the ability of adenosine A2 receptors to heteromerize with other G-protein coupled
receptors, such as dopamine, glutamate, cannabinoid and ATP receptors in the striatum [67].
The roles of these G-protein coupled receptors in blood vessels are not yet understood. It is un-
clear whether the agonistic effect of abacavir on adenosine A2 receptors may modulate the
functions of these receptors in blood vessels.
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